QuidelOrtho 10-Q: $124M Nine-Month Cash Burn, $2.94B Debt, China Revenue Down 42%
QDEL sits 30% above its 52-week low of $9.92 on elevated volume (1.9× avg).
Summary
QuidelOrtho's Q3 10-Q shows a $53.8 million quarterly loss on $618.9 million of revenue, but the bigger story is $124.0 million of nine-month operating cash burn, borrowings up to $2,937.3 million and China revenue down 42%.
Key Events · Earnings and Guidance · QDEL
-
Q3 Loss of $53.8M on $618.9M Revenue
Revenue fell 12% from $699.9 million a year earlier; the quarter's net loss was $53.8 million, or $0.78 per share, versus a $733.0 million loss a year ago that included a $700.7 million goodwill impairment.
-
Nine-Month Operating Cash Burn Widens
Net cash used for operating activities was $124.0 million versus $26.7 million a year earlier, driven by a $188.8 million inventory build and a $91.9 million swing in other liabilities.
-
Debt Rises, Revolver Availability Shrinks
Total borrowings rose to $2,937.3 million from $2,650.2 million, with $424.4 million now current; revolver availability fell to $367.0 million from $596.6 million against $166.4 million of cash.
-
China Revenue Down 42%
China segment revenue fell to $48.9 million from $84.6 million and segment Adjusted EBITDA fell 79% to $7.9 million after nationwide IVD pricing guidelines were finalized in mid-August 2026.
Analysis · QDEL · Life Sciences
The headline loss was already public, but the full 10-Q shows how thin the cushion is. Nine-month operating cash flow was negative $124.0 million versus negative $26.7 million a year earlier, inventories absorbed $188.8 million, and total borrowings climbed to $2,937.3 million from $2,650.2 million. Only $367.0 million remains available on the revolver, down from $596.6 million, against $166.4 million of cash. The September 23 covenant amendment buys room through 2029, but the leverage ceiling starts at 5.50x, which tells you where the balance sheet sits. China is the other hole: revenue fell 42% to $48.9 million and segment Adjusted EBITDA fell 79% to $7.9 million after the NHSA finalized nationwide IVD pricing guidelines in mid-August 2026. Management's answer is a new cost program launched in Q4 2026 targeting over $80 million of annual savings in 2027, at a cost of $30-$35 million of one-time charges.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QDEL was trading at $12.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.2M. The 52-week trading range was $9.92 to $35.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.